US Patent 6,863,891: Scope, Claim Boundaries, and US Landscape
US Patent 6,863,891 is directed to a treatment method for female infertility that uses a specific lyophilized (lyophilizate) formulation of cetrorelix administered during controlled ovarian stimulation to prevent premature ovulation. The claims are narrow in two ways: (1) they require the method context (female infertility under controlled ovarian stimulation) and (2) they require a defined composition attribute tied to the acetic acid content in the cetrorelix solution prior to lyophilization.
The core technical boundary is the phrase: “a lyophilizate of a certrorelix solution containing 100-10,000 parts by weight of acetic acid per part of dissolved cetrorelix.” Claim 2 adds a second boundary: the lyophilizate includes a bulking agent.
What does Claim 1 actually cover? (Method + formulation attribute)
Claim 1 recites a combination of four elements that must all be present for infringement:
- Treatment target and indication
- “A method of treating female infertility”
- Treatment setting
- “administering, to a female undergoing controlled ovarian stimulation”
- Drug form
- “an effective amount of pharmaceutical composition comprising a lyophilizate”
- Lyophilizate composition attribute
- the lyophilizate is specifically “of a certrorelix solution containing 100-10,000 parts by weight of acetic acid per part of dissolved cetrorelix,” and the method works “thereby preventing premature ovulation.”
Practical claim construction for scoping
- The claim is not limited to a specific route, dose size, dosing schedule, or device beyond “administering” and “effective amount.”
- The claim is limited to lyophilizates made from cetrorelix solutions with the specified acetic acid-to-cetrorelix mass ratio (100 to 10,000 parts by weight acetic acid per 1 part dissolved cetrorelix).
- The claim ties product attributes to function (“thereby preventing premature ovulation”), but the operative boundary is still the composition definition.
Composition ratio boundary: the key infringement lever
The acetic acid specification is expressed as a ratio, which is unusual compared with typical mg/mL or w/w percent ranges. In operational terms, it functions like a gating parameter for:
- whether the lyophilizate qualifies as the claimed material, and
- whether the method can be alleged to use the claimed pharmaceutical composition.
What does Claim 2 add? (Bulking agent requirement)
Claim 2 depends on Claim 1 and adds:
- “wherein the lyophilizate further comprises a bulking agent.”
This narrows coverage to lyophilized cetrorelix compositions that include at least one bulking agent as part of the lyophilizate formulation.
Scope split implied by dependence
- If a product uses the same controlled ovarian stimulation method and the same acetic acid ratio in the cetrorelix solution, it may fall within Claim 1 even if it uses a stabilizer system that is not characterized as a “bulking agent.”
- If it includes a bulking agent, it falls within Claim 2.
How tight is the claim on manufacturing details? (What must be “true” for literal coverage)
The claim requires that the lyophilizate is “of a certrorelix solution” with a specified acetic acid ratio. That means infringement analysis typically focuses on:
- Source solution composition prior to lyophilization
- acetic acid content must land within 100-10,000 parts by weight per part of dissolved cetrorelix.
- Lyophilizate identity
- the pharmaceutical composition must “comprise a lyophilizate of” that solution.
The claim does not explicitly recite:
- residual solvent levels,
- specific excipient identities beyond Claim 2’s “bulking agent,”
- particle size, cake structure, or reconstitution time.
It also does not state that acetic acid must be present after lyophilization at a particular residual level. It ties the ratio to the solution used to make the lyophilizate.
Where is the claim weakest for design-arounds? (Elements most likely to vary across competitors)
Across lyophilized peptide/gonadotropin-releasing hormone antagonist formulations, the most modifiable axis is excipient and process composition. Under these claims, however, design-arounds face two constraint types:
1) Indication and use constraints
The claims require:
- “female undergoing controlled ovarian stimulation,” and
- a method to prevent premature ovulation.
A competitor can potentially reduce exposure by changing the claimed use context (for example, a different clinical pathway not framed as controlled ovarian stimulation), but courts still look at what is actually done in practice and how it is marketed and labeled. The claim wording is use-focused.
2) Acetic acid ratio constraint (hard anchor)
The acetic acid-to-cetrorelix mass ratio is a specific numeric boundary. Altering this ratio is the direct way to move outside literal Claim 1 coverage:
- outside 100 to 10,000 parts by weight per part dissolved cetrorelix.
A competitor may try to keep formulation performance while shifting:
- salt selection (if acetic acid is replaced by another acid),
- concentration system,
- or the solution composition prior to lyophilization.
3) Bulking agent constraint (only Claim 2)
If a competitor uses a bulking system but does not label it as a “bulking agent,” Claim 2 risk may turn on how the excipient functions scientifically and how it is described. Claim 2 is narrower than Claim 1 because it adds an explicit excipient class.
What does this patent likely cover in the market (product profile inference from the claim)
Based on the claim language, the commercial embodiment is a lyophilized cetrorelix product intended for use during controlled ovarian stimulation to prevent premature LH-mediated ovulation.
The patent targets:
- an aqueous “cetrorelix solution” with a defined acetic acid ratio,
- lyophilization into a reconstitutable cake,
- optional bulking agent inclusion in Claim 2 versions.
The acetic acid ratio implies the formulation is designed around:
- peptide solubility and stabilization during solution preparation,
- pH control during manufacturing,
- lyophilization performance (e.g., cake formation and reconstitution).
How does this claim set interact with broader cetrorelix formulation IP? (Landscape logic)
US Patent 6,863,891 is a use claim tied to a specific formulation attribute. That generally puts it in a patent landscape position where it can:
- coexist with broader cetrorelix composition patents (active ingredient, general formulation),
- coexist with device or dosing regimen patents,
- compete with other formulation patents that use different acids/excipients or different process attributes.
Likely landscape categories you should map in the US
Even without restating unrelated patents, US landscape diligence typically segments cetrorelix patents into:
- Active ingredient and core use
- older cetrorelix discovery, initial fertility indications, general antagonist mechanism
- Formulation and stabilization
- salts, buffers, excipients, lyophilization support systems
- Method-of-use claims
- clinical use during ovarian stimulation and prevention of premature ovulation
- Manufacturing/process claims
- solution preparation parameters, lyophilization parameters, reconstitution characteristics
6,863,891 sits in (2) plus (3): formulation tied to a method. That can be more enforceable than purely composition-only claims because it can anchor infringement to administration in a clinical setting.
What are the enforceable claim boundaries for a generic or follow-on product?
A generic holder selling a product for controlled ovarian stimulation will raise two questions:
- Does the administered product contain a lyophilizate made from a cetrorelix solution meeting the acetic acid ratio?
- Does the use match the “female infertility” + “controlled ovarian stimulation” + “preventing premature ovulation” method context?
Infringement risk matrix tied to claim elements
| Scenario |
Acetic acid ratio matches 100-10,000 parts by weight per part cetrorelix (solution used to make lyophilizate) |
Patient context matches controlled ovarian stimulation and premature ovulation prevention |
Bulking agent present |
| Designed to match all |
Yes |
Yes |
Yes or No (Claim 1 only needs No/Yes) |
| Matches method context but changes acetic acid ratio |
No |
Yes |
Either |
| Matches formulation acid ratio but changes use context |
Yes |
No |
Either |
| Matches Claim 1 material but excludes bulking agent |
Yes |
Yes |
No |
| Matches Claim 1 but includes bulking agent |
Yes |
Yes |
Yes |
- Claim 1 is implicated if the product’s lyophilizate origin matches the acetic acid ratio and it is administered in the claimed clinical context.
- Claim 2 further requires bulking agent presence.
How does claim wording create evidentiary burden? (What gets litigated)
For this type of claim, litigation often turns on:
- composition characterization (what acid system was used for the solution),
- manufacturing records linking the product lot to the claimed solution composition,
- and use evidence (prescribing label, clinical protocol, and actual administration for controlled ovarian stimulation).
The acetic acid ratio is objective and numeric. That can drive discovery requests for:
- formulation worksheets,
- batch records,
- input solution specifications.
Key Takeaways
- US Patent 6,863,891 covers a method of treating female infertility during controlled ovarian stimulation by administering a lyophilized cetrorelix composition made from a cetrorelix solution containing 100-10,000 parts by weight acetic acid per part dissolved cetrorelix, to prevent premature ovulation.
- Claim 2 narrows that coverage to lyophilizates that also include a bulking agent.
- The most direct design-around lever is the acetic acid ratio in the solution used to produce the lyophilizate. The most direct clinical-context lever is avoiding the framed use in controlled ovarian stimulation for premature ovulation prevention.
- The patent’s enforceability in practice will hinge on evidence connecting product lots to the claimed solution acid ratio and evidence that administration aligns with the controlled ovarian stimulation use context.
FAQs
1) What is the single most important numeric limitation in US 6,863,891?
The acetic acid content in the cetrorelix solution used to make the lyophilizate: 100-10,000 parts by weight acetic acid per part of dissolved cetrorelix.
2) Does Claim 1 require a bulking agent?
No. Bulking agent is only required in Claim 2.
3) Is this a composition patent or a use patent?
It is a method of treatment claim tied to a composition attribute of the administered drug (lyophilizate made from a cetrorelix solution with a defined acetic acid ratio).
4) Can a product avoid infringement by changing the formulation excipients while keeping the same acetic acid ratio?
Changing other excipients alone does not remove Claim 1 risk if the lyophilizate still originates from a cetrorelix solution with the required acetic acid ratio. For Claim 2, bulking agent inclusion affects risk.
5) What clinical context must the accused method match?
The method must involve administering to a female undergoing controlled ovarian stimulation to prevent premature ovulation.
References (APA)
[1] US Patent 6,863,891 (claims as provided in prompt).
